Skin Cancer | Topics

Duration of Treatment for Melanoma
November 02, 2021

John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.

Taking Drug Holidays Amidst Melanoma Therapy
November 02, 2021

Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.

How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell Carcinoma
October 19, 2021

A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.

Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy
July 31, 2021

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.

FDA Expands Indication for Pembrolizumab in Locally Advanced CSCC
July 06, 2021

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC
April 11, 2021

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma
February 11, 2021

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC
February 09, 2021

The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.

Looking at MCC Diagnoses Over Time Reveal Varying Effects Account for Incidence Rates
January 11, 2021

A study published in JAMA Dermatology found changes in diagnostics and awareness may, in part, account for initial increases in incidence rates for Merkel cell carcinoma.

Study Finds Incidence Rates of cSCC Continue to Increase, Especially Among Females
November 16, 2020

Study investigators indicated that these results call for the need to revise skin cancer health policies to be able to handle the increasing burden of keratinocyte carcinoma management.